Insights into the Sage Therapeutics Class Action Lawsuit
Shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE) are encountering significant updates regarding a class action lawsuit that may impact their investment decisions. This company is known for its innovative treatments for complex neurological disorders, making the current developments especially relevant for investors.
Key Information to Consider
The Gross Law Firm has issued a notice to shareholders, highlighting an important deadline to select a lead plaintiff in the ongoing class action lawsuit. The notice specifically urges those who purchased SAGE shares during a certain class period to get in touch with the firm. It’s crucial to understand that you don’t have to be involved as a lead plaintiff to seek recovery.
Class Period Overview
The defined class period for this lawsuit runs from April 12, 2021, to July 23, 2024. During this time, various allegations have surfaced that could greatly affect the company’s claimed effectiveness and market presence.
Allegations Presented Against Sage Therapeutics
The complaint's key allegations contend that Sage Therapeutics, through its executives and representatives, made misleading statements and failed to share vital information about its treatments. For instance, Zuranolone, a neuroactive steroid designed for postpartum depression, is alleged to be less effective for treating Major Depressive Disorder (MDD) than previously claimed. Concerns have also been raised regarding the FDA potentially rejecting Zuranolone’s New Drug Application (NDA) for MDD, alongside exaggerated clinical outcomes.
Moreover, Sage Therapeutics is under scrutiny for its other products, including SAGE-718 and SAGE-324, which are likewise accused of being less effective than what has been publicly stated. There is a prevailing worry that investor confidence has been artificially buoyed due to these alleged misrepresentations.
Crucial Deadline for Shareholders
Investors are encouraged to act quickly, as the crucial deadline is October 28, 2024. This date represents the last chance for shareholders to join the class action proceedings as lead plaintiffs.
Steps for Affected Investors
If you register during the specified period, there are no fees or obligations involved. After registering, you will gain access to a portfolio monitoring tool that will keep you updated on the ongoing legal situation. This service ensures you stay informed about significant updates relating to your investment and the lawsuit's progress.
Why Trust Gross Law Firm?
The Gross Law Firm is committed to representing investor interests, emphasizing the importance of ethical business practices and accurate disclosures from corporations. With extensive experience in navigating the complicated realm of securities law, the firm is dedicated to advocating for investors who have suffered financial setbacks due to misleading or fraudulent company statements.
How to Contact Gross Law Firm
If you need more information or wish to register as a prospective participant in the lawsuit, please reach out to the Gross Law Firm. They are located at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the objective of the class action lawsuit?
The class action lawsuit is aimed at holding Sage Therapeutics accountable for alleged misleading statements that may have caused financial losses to shareholders.
When is the registration deadline for the lawsuit?
The deadline to register as a lead plaintiff in the class action is October 28, 2024.
Do I need to be a lead plaintiff to be involved?
No, being appointed as a lead plaintiff isn't necessary to benefit from any potential recovery from the lawsuit.
What should I do if I purchased shares of Sage Therapeutics?
If you bought shares during the class period, it's advisable to register for the class action and keep track of the case's development.
How can the Gross Law Firm assist me?
The Gross Law Firm can guide you through the legal process, making sure your rights as an investor are upheld and that you remain well-informed throughout the proceedings.
